VSEL QiGen Regenerative Medicine Services
VSEL therapy is one of the most exciting regenerative medicine therapies. A VSEL is a very small “embryonic-like” cell – a type of stem cell that has the greatest potential to regenerate and rejuvenate tissues throughout the entire human body. Since these cells are small yet powerful, they can pass through the lungs and brain where other stem cells do not. They are also very robust as when they reach their target they are known to be able to both rapidly multiply and grow in size to produce healing proteins. VSELs are what is known as pluripotent (can become nearly any tissue or organ) and therefore do not have the risk of tumor formation which is a potential complication of using embryonic stem cells. While VSELs are found in the bone marrow and blood, they are usually bound and thus stay intact and young, so even the elderly have these healthy and powerful stem cells. Furthermore, VSELs that we use are autologous (derived from your own plasma) which only enhances their safety profile.
But typically, VSELs are bound in the plasma and are not very available for use in the body’s regenerative functions. However, our colleague Dr. Todd Ovokaitys and his team at Johns Hopkins developed the patented QiGen laser system to release millions of VSELs from the patient’s own plasma that can be used to restore and rejuvenate the body. In fact, Dr. Ovokaitys has worked with leading scientists such as Harvard University professor David Sinclair and has validated that this treatment can reverse biological and cellular age as measured by DNA methylation. The age reversal effect on the body is typically 3 years per treatment within 6-12 weeks, the most that has been observed thus far with a method, especially that can offer repeated treatments. This is the most profound effect of being able to turn back the biological clock throughout the body that may allow a person to live a lot longer in a much more youthful body than has ever been available. Thousands of procedures have been performed to date and we are proud to be selected as one of the few clinical sites in the country to be granted a QiGen system.
While some patients may experience relief of their symptoms and note improved energy and cognition after one treatment, the number of treatments depends on the patient’s condition and longevity/anti-aging goals. These treatments can be performed every few months and side effects are limited to fatigue and malaise in under 10% of the patients who received the procedure.
The VSELs are prepared by drawing blood into specifically designed tubes from Israel, extracting the PRP, and then applying the laser to fractionate out the VSELs. The VSEL treatment can be given by injection into joints, hair, skin, ear, and sexual organs among other areas to help with regeneration but is typically given intravenously (IV). The interesting thing about this aspect of the IV procedure is that we utilize the laser to direct the IV treatment of VSELs to target areas of the body that need regeneration. This innovative technique is also protected by a US patent.
Dr. Ovokaitys published a clinical study of using this method to improve function in severe end stage heart failure. A normal heart pumps 50-65% of its blood each beat, and this percentage is called the ejection fraction. Less than 30% is considered severe heart failure. The study subjects had an average of a 21% ejection fraction and were all heart transplant candidates. Compared to other published work where intracoronary stem cells were delivered by invasive cardiac catheterization and gave an improvement of only 8% overall function in 6 months, our much simpler and safer intravenous delivery gave an average improvement of 50% in 3 months. Half the subjects improved off of the heart transplant list and 20% improved to nearly normal with just one treatment. The prognosis in severe heart failure in only 30% one year survival, and little or no survival after 3 years. In contrast we showed an 80% survival rate after 6 years, which is unprecedented in this area. A heart transplant costs $1 million dollars and only 10% of candidates live long enough to get a transplant. Our procedure costs 99% less and nearly 100% of persons who could benefit could be able to receive the treatment.
- Macular degeneration
- Autoimmune diseases
- Cardiomyopathy (heart failure)
- Some forms of liver and kidney failure